DSM-5 Criteria for Bipolar Disorder
DSM-5 diagnostic criteria checklist for Bipolar I (manic episode required) and Bipolar II (hypomanic + depressive episode required) disorders. Distinguishing features of mania vs hypomania are duration and impairment.
Score interpretation
Insufficient criteria for bipolar disorder
→ Consider cyclothymia, ADHD, substance use, personality disorder, thyroid disease; MDQ screening; monitor longitudinally
Significant manic/hypomanic symptoms — bipolar disorder likely
→ Urgent psychiatry referral; mood stabiliser (lithium, valproate, quetiapine); NEVER start antidepressant alone in bipolar (risk of manic switch); safety assessment; driving notification requirements; risk of suicide and impulsive behaviour; family psychoeducation; MDQ and lifetime history review
Interpretation bands for the DSM-5 Bipolar. Apply clinical judgement and local guidance.
References
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5). 2013.
Related
Curated clinical cross-links plus same-class fallbacks.
- Carbamazepine (Psychiatric Use) · Mood Stabiliser (Sodium Channel Blocker) — Bipolar Disorder
- Risperidone (Paediatric) · Atypical Antipsychotic — Autism Spectrum Disorder / Schizophrenia / Tic Disorders
- Carbamazepine (Paediatric) · Antiepileptic — Focal Seizures / Trigeminal Neuralgia / Bipolar Disorder
- Lamotrigine (Psychiatric Use) · Mood Stabiliser (Sodium Channel Blocker) — Bipolar Depression
- Sodium Valproate · Antiepileptic / Mood stabiliser
- Tetrabenazine · VMAT2 Inhibitor — Hyperkinetic Movement Disorders
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.